Healthcare Sector Valuation Discount Vanishes as Defensive Capital Accelerates Inflows
nashnova research
The healthcare sector's forward P/E has climbed to 19.3×, erasing a 25% discount to the S&P 500 in just one year, as investors increasingly use healthcare stocks to hedge against a potential AI-trade unwind.
How did a 25% valuation discount vanish in one year?
Per FactSet, the Health Care Select Sector SPDR ETF (XLV) now trades at a 19.3× forward P/E — slightly above the S&P 500. A year ago the sector carried a 25% discount.
This means → the market has re-priced healthcare from "cheap defensive filler" to "safety worth paying a premium for."
On Monday alone XLV rose over 2%, with Moderna up 6.7% and Bristol-Myers Squibb up 4.9% — the pace of inflows is accelerating.
Why is money moving from tech into healthcare?
The core logic: rising rates may squeeze AI capital spending. Investors worried about an AI-trade collapse are pulling out of high-volatility tech stocks.
In plain terms = AI stocks depend on the story that massive future spending will yield massive returns. Higher rates raise the cost of that spending, making the story less compelling.
The destination is sectors with more stable earnings and less cyclicality — healthcare fits that profile.
Has this pattern appeared before?
Goldman Sachs U.S. healthcare research head Asad Haider notes that healthcare sustains a valuation premium only when three conditions align: ① confidence in medical innovation, ② doubt about other sectors' earnings durability, ③ manageable policy uncertainty. He believes all three are now broadly in place.
Historical premium periods cluster around 2003–2007 and 2013–2015. The closest parallel to today is the mid-2000s — the Fed was hiking, a housing boom sustained profits, much like today's AI-driven boom.
This reflects a recurring pattern: healthcare premiums tend to emerge when "the other boom story starts feeling fragile" — last time it was housing, this time it is AI.
Which companies anchor the sector's fundamentals?
Johnson & Johnson expects double-digit sales growth by decade-end. Eli Lilly, powered by surging demand for diabetes and obesity drugs Mounjaro and Zepbound, projects sales growth exceeding 30% this year.
Together they account for roughly 25% of XLV's weighting. In plain terms = a quarter of this ETF's performance hinges on two companies — their results directly drive sector valuation.
Does "defensive" mean zero risk?
The policy backdrop is currently favorable: over ten drugmakers have struck deals with the Trump administration, trading price concessions for tariff exemptions. Mizuho strategist Jared Holz says pharma and device makers face their most stable policy environment in years.
But risks remain: as the 2028 primaries approach, "Medicare for All" rhetoric could resurface, pressuring insurers like UnitedHealth Group and Humana.
This means → history offers a warning too: investors who rotated into healthcare in early 2006 underperformed the broader market for nearly two years, until the financial crisis finally proved the sector's resilience. Rotating early = paying an opportunity cost; but if the AI trade does unwind, buying at today's slight premium may look reasonable in hindsight.
市场有风险，内容仅供研究参考，不构成投资建议。